The deal, which has been in the works for months, hands the German pharmaceutical company two approved drugs for rare tumors.

Sen. Bill Cassidy’s report calls on Congress to improve the transparency of the drug discount program in a move praised by ...

Interim results from a study in China suggest ivonescimab may reduce the risk of death versus Keytruda, but the difference ...

The Commerce Department has begun a so-called Section 232 investigation into the national security effects of the U.S.

The drug, being developed for a rare genetic disorder and currently under review in the U.S., is seen by some investors as ...

The biotech is using AI and a trove of health data to better understand why certain conditions progress and intervene ...

The CRISPR company is laying off about a third of its employees and stopping work on an experimental lupus treatment in a bid ...

Net sales of Cobenfy, whose success is imperative for Bristol Myers, totaled $27 million in the first quarter, handily ...

The company is looking to the highly anticipated launch of a closely watched HIV medicine to offset weakening demand for ...

The company reiterated its financial outlook for the year but is struggling to predict the likely impact of pharmaceutical ...

The drugmaker absorbed additional tariff-related costs in the first quarter, but has taken steps to lower the financial ...

The data could help the Enhertu regimen overtake a drug combination that’s been used as the initial treatment for ...